此外，在一项引人注目的概念验证实验中，团队将连接石墨烯的大脑类器官整合到一个配备环境传感器 的机器人系统中。当机器人探测到前方障碍物时，会自动发送光信号刺激类器官，类器官随即产生特定 的神经活动模式，触发机器人改变行进路线，整个感知—反应循环在短短50毫秒内完成。这一成果预示 着未来可能出现的神经生物混合系统，活体神经组织将与机器人协同工作。 这项研究标志着石墨烯在神经科学、纳米技术和神经工程领域的应用取得重要突破，有望发展为研究神 经退行性疾病和发育性脑病的强大平台，还可拓展至组织工程领域。 （文章来源：科技日报） 美国加州大学圣迭戈分校桑福德干细胞研究所研发了一种石墨烯介导的光刺激（GraMOS）新技术，能 加速大脑类器官发育和成熟。这是一种安全、非遗传、生物相容且无破坏性的技术，能够在数天至数周 内有效调控神经活动。该技术为理解阿尔茨海默病等神经退行性疾病如何破坏大脑回路提供了新视角， 还能实现类器官对机器人设备的实时控制。相关研究成果发表于新一期《自然·通讯》杂志。 该技术能够在不改变细胞遗传密码的前提下，显著加快大脑类器官的成熟过程，从而为神经系统疾病的 研究、脑机接口开发以及活体神经组织与技术系统 ...

Group 1 - The core viewpoint of the article highlights a significant increase in licensing and transfer transactions in China's biotechnology and pharmaceutical industry, with a total transaction amount rising 135% year-on-year to $60 billion [1] - The initial public offering of Heng Rui Pharmaceutical on the Hong Kong Stock Exchange contributed to a 42.9% year-on-year increase in financing for innovative drugs in China's primary market, totaling $3.33 billion, although the number of financing events slightly decreased by 6.7% [1] - The improvement in the domestic financing environment and the upward trend in licensing transactions are expected to gradually lead to higher demand for domestic Contract Research Organization (CRO) services [1] Group 2 - The company WuXi AppTec is expected to continue gaining market share due to its integrated platform and strong operational efficiency, prompting an upward revision of its long-term revenue forecast [1] - The long-term earnings per share compound annual growth rate for WuXi AppTec has been adjusted to 16.2% for the period from 2025 to 2032, with target prices for its H-shares and A-shares increased to HKD 123 and CNY 114.4 respectively [1] - WuXi Biologics' revenue forecast for 2025 to 2027 has been raised by 2% to reflect preliminary performance for the first half of 2025, with the target price increased to HKD 35, although it maintains a "neutral" rating due to high valuation [1]

Core Viewpoint - CrystalTech Holdings has completed the acquisition of Liverpool ChiroChem (LCC), enhancing its capabilities in the exploration of chemical spaces through its "AI + Robotics" intelligent autonomous experimental platform [1] Group 1: Company Overview - CrystalTech is a comprehensive platform company integrating "quantum physics + AI + robotics," utilizing quantum algorithms as its technical foundation [1] - The company has achieved rapid revenue growth, surpassing the commercialization threshold, with projected revenue of 266 million yuan in 2024, representing a year-on-year increase of 52.75% [1] - The client base includes 16 of the top 20 global biotechnology and pharmaceutical companies, establishing long-term partnerships with industry leaders such as Pfizer, Johnson & Johnson, and Merck Group [1] Group 2: Competitive Advantages - The company's core competitive advantages are driven by technological innovation, data barriers, and algorithm superiority [2] - Technological innovation is exemplified by the creation of a "quantum physics + AI + robotics" R&D platform [2] - Data barriers are established through a "high-throughput experiment - high-quality data - high intelligent model" flywheel, with the robotic laboratory operating 24/7 and accumulating over 200,000 reaction process data points monthly [2] - Algorithm superiority is highlighted by the global-leading protein interaction prediction algorithm XtalFold, with commercial licensing agreements with multinational pharmaceutical companies [2] Group 3: Revenue Forecast - As a leader in AI for Science, the company is expected to deepen the application of AI + robotics technology across various fields, with projected revenues of 424 million, 676 million, and 957 million yuan for 2025, 2026, and 2027, respectively [2]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [4]. Core Insights - The company has completed the acquisition of Liverpool ChiroChem (LCC), enhancing its capabilities in the field of chiral molecule research and development [2]. - The company operates as a comprehensive platform integrating quantum physics, AI, and robotics, which forms a complete loop of algorithm simulation and experimental validation [2][3]. - The company has established long-term partnerships with 16 of the top 20 global biotechnology and pharmaceutical companies, including Pfizer and Johnson & Johnson [3]. - The company is recognized as a leader in "AI for Science," with significant revenue growth projected, reaching CNY 266.43 million in 2024, a year-on-year increase of 52.75% [4]. Financial Summary - The company’s revenue is expected to grow significantly, with projections of CNY 424.07 million in 2025, CNY 676.38 million in 2026, and CNY 957.43 million in 2027, reflecting growth rates of 59.16%, 59.50%, and 41.55% respectively [5][10]. - The net profit attributable to the parent company is forecasted to improve from a loss of CNY 1,914.38 million in 2023 to a profit of CNY 60.34 million by 2027 [5][10]. - The company’s earnings per share (EPS) is projected to transition from a loss of CNY 3.96 in 2023 to a profit of CNY 0.02 by 2027 [5][10]. Market Data - As of June 18, 2025, the closing price of the stock was HKD 5.95, with a 12-month price range of HKD 3.26 to HKD 15.60 [6]. - The total market capitalization of the company is approximately HKD 23,917.88 million [6].

Core Viewpoint - The collaboration between Fudan University and Shanghai Xiaohai Turtle Technology Co., Ltd. has led to the development of R³Net, a robust quantitative method based on a three-phase neural network for processing noisy cdPCR images [1][2]. Group 1: Technology Overview - R³Net employs a three-stage processing workflow: noise recognition, image restoration, and chip reading. It utilizes a U-Net network for precise noise area identification and generates noise masks, followed by an innovative S-SRNet for image restoration, and finally a lightweight YOLO-mini network for high-precision quantitative analysis [3]. - The unique aspect of this technology is its temporal input mechanism, which allows the network to effectively distinguish between foreground noise and background areas by inputting noisy images and noise masks at different time steps [3]. - The introduction of Spiking Neural Networks (SNN) enhances computational efficiency and temporal sensitivity, providing a new solution for image processing in complex noise environments [3]. Group 2: Performance Metrics - Extensive testing on DNA samples from lung cancer, COVID-19, and influenza viruses shows that R³Net outperforms traditional methods in key metrics: it achieves an accuracy rate of 88.47% when processing interfered images, with clarity and similarity indices of 41.38 and 99.72, respectively [4]. - The lightweight algorithm maintains a high precision of 98.27% while reducing system resource usage by over 98% compared to traditional methods, processing an image in just 1.3 seconds, thus meeting the demands for rapid clinical testing [4]. - The application of R³Net technology signifies that reliable detection results can be obtained even in complex experimental environments, marking the entry of digital PCR into an AI-driven era [4].

特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 分子互作是指不同分子之间相互识别结合及解离的过程。研究分子间相互作用不仅有助于阐明生物反应机理、探究疾病发生机制，而且能够揭 示生命现象的本质。长久以来，对各种生物分子间相互作用的探究一直是科学家们最关注的焦点之一。 为帮助广大实验室用户及时了解分子互作创新技术及前沿应用，仪器信息网将于 2 0 2 5年4月1 0 - 11日 举办"第三届分子互作技术及应用进展"主 题网络研讨会，围绕 分子互作新技术新方法 、以及在 分子垂钓、药物研发、生物医学和结构生物学 等领域的应用进展进行探讨交流，为科研 工作者和相关从业人员搭建一个即时、高效的交流和学习的平台。 核心看点： ◆1 0大技术巡礼： SPR技术、BLI技术、MST技术、AUC技术、SpS技术、Me t aSPR技术、FIDA技术、SERSc r e e n技术、FRET成像分析技 术以及超高通量分子相互作用技术 ◆四个主题会场： "分子垂钓/抑制剂筛选新方法"、"分子互作驱动药物新发现"、"生物医学前沿进展"、"分子互作与结构前沿 ...